SCHEMBL452301

SCHEMBL452301

[c]1[c]c2ccccc2nc1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.33
ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3929427 0.71 FGFR1 (0.30)
SCHEMBL3938300 0.68 ALDH1A1 (0.38) MAPTALDH1A1
SCHEMBL6345969 0.68 NUDT1 (0.31) MAPT
SCHEMBL451695 0.68 MAPT (0.39) MAPTALDH1A1
SCHEMBL1569404 0.65
SCHEMBL82882 0.62 EGFR (0.37) MAPTALDH1A1
SCHEMBL450208 0.62 GPR3 (0.35) MAPT
SCHEMBL8727 0.62 ALDH1A1 (0.41) MAPTALDH1A1
SCHEMBL1395756 0.62 MAPT (0.33) MAPT
SCHEMBL9870917 0.61 NPC1 (0.39) MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0869700-B1 Electroluminescent devices XEROX CORP (US) 2004-03-17 EP claimed
US-5932363-A LUMINESCENT COMPOSITION COMPRISED OF MIXTURE OF FLUORESCENT DYE AND SPECIFIED METAL CHELATE COMPOUND XEROX CORPORATION (US) 1999-08-03 US claimed
US-5925472-A Electroluminescent devices XEROX CORPORATION (US) 1999-07-20 US claimed
EP-0869700-A2 Electroluminescent devices Xerox Corporation (US) 1998-10-07 EP claimed
WO-1998033382-A1 FUNGICIDAL COMPOSITIONS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-08-06 WO claimed
WO-1998023155-A1 ARTHROPODICIDAL AND FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-06-04 WO claimed
EP-0825992-A1 FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1998-03-04 EP claimed
WO-1996036633-A1 FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-11-21 WO claimed
WO-1996036229-A1 FUNGICIDAL CYCLIC AMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1996-11-21 WO claimed
US-20150216861-A1 CYCLOPROPYL AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2015-08-06 US disclosed
US-9029381-B2 Cyclopropyl amide derivatives ASTRAZENECA AB (SE) 2015-05-12 US disclosed
EP-2805937-A1 Cyclopropyl amide derivatives AstraZeneca AB (SE) 2014-11-26 EP disclosed
EP-2253615-B1 Cyclopropyl amide derivatives ASTRAZENECA AB (SE) 2014-07-09 EP disclosed
EP-2195293-B1 CYCLOPTOPYL AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2013-10-16 EP disclosed
US-5942340-A CHARGE TRANSPORTING COMPONENT CONTAINING INDOLOCARBAZOLE COMPOUND; ENHANCED THERMAL AND OPERATIONAL STABILITY, DURABILITY XEROX CORPORATION (US) 1999-08-24 US disclosed
US-5932363-A LUMINESCENT COMPOSITION COMPRISED OF MIXTURE OF FLUORESCENT DYE AND SPECIFIED METAL CHELATE COMPOUND XEROX CORPORATION (US) 1999-08-03 US disclosed
US-5925472-A Electroluminescent devices XEROX CORPORATION (US) 1999-07-20 US disclosed
EP-0906947-A1 Indolocarbazole electroluminescent devices XEROX CORPORATION (US) 1999-04-07 EP disclosed
EP-0906948-A1 Electroluminescent devices Xerox Corporation (US) 1999-04-07 EP disclosed
EP-0869700-A2 Electroluminescent devices Xerox Corporation (US) 1998-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150216861-A1 CYCLOPROPYL AMIDE DERIVATIVES HRH4, HRH2, HRH3 MAPT 1670/4885ALDH1A1 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.